NXE’149 and other GPR52 agonists within the portfolio were designed by Nxera using its world-leading NxWave™ structure-based drug design platform to improve patient outcomes by simultaneously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback